Celltrion’s Yuflyma (biosimilar, adalimumab) Receives Health Canada's Approval for the Treatment of Chronic Inflammatory Diseases
Shots:
- Health Canada granted a notice of compliance for Yuflyma & the approval was based on the results of analytical, preclinical/clinical studies evaluating Yuflyma vs Humira (adalimumab) in patients with multiple chronic inflammatory diseases
- The results showed that Yuflyma is comparable to Humira (adalimumab) in terms of safety, efficacy, PK/PD, and immunogenicity for ~24wks. and 1yr. following treatment
- Yuflyma is an adalimumab biosimilar with a high-concentration, low-volume and citrate-free formulation & has been approved across all 10 indications for multiple chronic inflammatory diseases, including RA, polyarticular JIA, PsA, AS, CD, UC, HS, PsO, adult uveitis, and pediatric uveitis
Ref: Newswire.Ca | Image: Celltrion
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com